10 articles
Inspire's Q1 2026 print attributes a combined $120 to $150 million FY26 hit to WISeR plus coding uncertainty, six sell-side analysts cut targets through 7 May, and NeuroPace just received a 43% to 47% Medicare reimbursement increase on the same rule cycle.
The State Council's biomedical-new-technologies regulation took effect 1 May 2026, letting Chinese hospitals charge for BCI commercially after a translation approval. Foreign-invested enterprises remain locked out.
The Senate passed H.814 in concurrence with the House on 6 May. What now sits with Governor Scott is a 6-page recognition statute, with the enforcement layer stripped in committee.
The provisional agreement reached on 7 May 2026 pushes high-risk AI obligations by 16 to 24 months, including the rules that capture Class IIb and Class III medical-device BCIs.
A Government Accountability Office report warns that the FDA has no framework for augmentation uses of brain-computer interfaces, even as military and commercial applications advance.
U: The Mind Company began taking orders for a consumer neuromodulation device on March 18, marketing bold clinical claims that have not appeared in peer-reviewed literature. An FDA submission is planned for 2027.
The agency's new policy ending the two-trial requirement was written for drugs, but brain implant makers watching Synchron, Neuralink, and Paradromics navigate FDA are asking whether the same logic could eventually ease their path.
In just nine months China has issued a national BCI blueprint, overtaken the United States in BCI patent filings, funnelled hundreds of millions into startups, and has just granted the world's first commercial implant approval.
New guidance expands the 'general wellness' exemption for wearables and loosens oversight of AI clinical decision tools — with major implications for every company building consumer neurotechnology.
Seven Chinese government bodies have released guidelines establishing a roadmap for brain-computer interface development, with BCI procedures now receiving medical insurance reimbursement in parts of the country.
Get the latest BCI news, breakthroughs, and market moves delivered to your inbox.
No spam. One-click unsubscribe. We respect your privacy.